Monte Rosa Therapeutics GLUE Stock
Monte Rosa Therapeutics Price Chart
Monte Rosa Therapeutics GLUE Financial and Trading Overview
| Monte Rosa Therapeutics stock price | 17.59 USD |
| Previous Close | 19.71 USD |
| Open | 19.66 USD |
| Bid | 14.16 USD x 200 |
| Ask | 23.88 USD x 200 |
| Day's Range | 18.63 - 19.86 USD |
| 52 Week Range | 4.09 - 25.77 USD |
| Volume | 975.62K USD |
| Avg. Volume | 990.26K USD |
| Market Cap | 1.66B USD |
| Beta (5Y Monthly) | 1.624 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.48 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.33 USD |
GLUE Valuation Measures
| Enterprise Value | 1.04B USD |
| Trailing P/E | N/A |
| Forward P/E | -10.838899 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 38.686707 |
| Price/Book (mrq) | 3.177706 |
| Enterprise Value/Revenue | 24.164 |
| Enterprise Value/EBITDA | -7.417 |
Trading Information
Monte Rosa Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.624 |
| 52-Week Change | 338.00% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 25.77 USD |
| 52 Week Low | 4.09 USD |
| 50-Day Moving Average | 18.25 USD |
| 200-Day Moving Average | 14.93 USD |
GLUE Share Statistics
| Avg. Volume (3 month) | 990.26K USD |
| Avg. Daily Volume (10-Days) | 851.84K USD |
| Shares Outstanding | 84.48M |
| Float | 52.94M |
| Short Ratio | 18.67 |
| % Held by Insiders | 0.59% |
| % Held by Institutions | 113.10% |
| Shares Short | 14.96M |
| Short % of Float | 17.98% |
| Short % of Shares Outstanding | 17.70% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1188.45% |
| Gross Margin | -238.53% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.40% |
| Return on Equity (ttm) | -32.62% |
Income Statement
| Revenue (ttm) | 42.95M USD |
| Revenue Per Share (ttm) | 0.49 USD |
| Quarterly Revenue Growth (yoy) | -95.00000000000000000000000000000000% |
| Gross Profit (ttm) | -102460000 USD |
| EBITDA | -139940992 USD |
| Net Income Avi to Common (ttm) | -130014000 USD |
| Diluted EPS (ttm) | -1.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 666.22M USD |
| Total Cash Per Share (mrq) | 7.89 USD |
| Total Debt (mrq) | 39.06M USD |
| Total Debt/Equity (mrq) | 7.49 USD |
| Current Ratio (mrq) | 9.538 |
| Book Value Per Share (mrq) | 6.19 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14675000 USD |
| Levered Free Cash Flow (ttm) | -77161752 USD |
Profile of Monte Rosa Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 321 Harrison Avenue |
| ZIP | 02118 |
| Phone | 617 949 2643 |
| Website | https://www.monterosatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 187 |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Q&A For Monte Rosa Therapeutics Stock
What is a current GLUE stock price?
Monte Rosa Therapeutics GLUE stock price today per share is 17.59 USD.
How to purchase Monte Rosa Therapeutics stock?
You can buy GLUE shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Monte Rosa Therapeutics?
The stock symbol or ticker of Monte Rosa Therapeutics is GLUE.
Which industry does the Monte Rosa Therapeutics company belong to?
The Monte Rosa Therapeutics industry is Biotechnology.
How many shares does Monte Rosa Therapeutics have in circulation?
The max supply of Monte Rosa Therapeutics shares is 84.48M.
What is Monte Rosa Therapeutics Price to Earnings Ratio (PE Ratio)?
Monte Rosa Therapeutics PE Ratio is now.
What was Monte Rosa Therapeutics earnings per share over the trailing 12 months (TTM)?
Monte Rosa Therapeutics EPS is -1.48 USD over the trailing 12 months.
Which sector does the Monte Rosa Therapeutics company belong to?
The Monte Rosa Therapeutics sector is Healthcare.
Monte Rosa Therapeutics GLUE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}